[Business Leader] TiumBio: "Leveraging First Domestic New Drug Development Experience to Become a Global Drug Developer"
Predicted impact: Low
Business leader interview with no financial or deal content.
TiumBio티움바이오
321550 · KOSDAQ · ₩321550 · 티움바이오
₩4,045▼ ₩35 (0.86%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −36.40%
- Market cap
- ₩122B
- Enterprise value
- ₩104B
- P/E
- —
- P/B
- 3.4×
- Dividend yield
- 0.0%
- ROE
- −51.0%
- Net margin
- −122.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.5% from the high
₩3,415Today: ₩3,975 – ₩4,190₩13,700
Returns
- 1W−4.8%
- 1M−8.9%
- 3M−1.2%
- 6M−66.3%
- YTD−32.5%
- 1Y−34.4%
- Volume today
- 48,134
- 0.5× the 20-day average
- Traded today
- ₩196M
- Listed shares
- 30,038,475
- EPS (12 months)
- −₩613
- Earnings yield −15.1%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: A business interview about future plans and a routine holding filing, with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-13.3% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
TiumBio stock overview
TiumBio (티움바이오, KRX: 321550) is listed on KOSDAQ, in the Biotech & Pharma sector. Tiumbio is a Korean biopharmaceutical company that researches and develops treatments for rare and intractable diseases, using both small-molecule synthetic drugs and biologic drugs. Its shares closed at ₩4,045 on Oct 26, 2026, down 0.86% on the day, giving it a market value of ₩122B.
Key facts
- Market cap
- ₩122B
- Sector
- Biotech & Pharma
- Latest price change
- −0.86%
- As of
- Oct 26, 2026
- Main business
- Tiumbio is a Korean biopharmaceutical company that researches and develops treatments for rare and intractable diseases, using both small-molecule synthetic drugs and biologic drugs.
Quick answers about TiumBio
- What does TiumBio do?
- Tiumbio is a Korean biopharmaceutical company that researches and develops treatments for rare and intractable diseases, using both small-molecule synthetic drugs and biologic drugs. Its lead pipeline candidate, Tosposertib (TU2218), is a dual TGF-beta and VEGF inhibitor being developed as an anticancer immunotherapy, and the company also runs a natural cosmetics OEM/ODM business and a contract analytical development organization for biopharmaceuticals.
- What is the market cap of TiumBio?
- The market capitalisation of TiumBio was ₩122B at the close on Oct 26, 2026.
- Who are the largest shareholders of TiumBio?
- According to the latest official filings, the largest reported holders are Kim Hun-taek (28.25%, as of Jun 24, 2026); Korea Investment Global Pharmaceutical Industry Growth Private Equity Investment Trust (1.74%, as of Apr 28, 2025); Song In-young (0.54%, as of Sep 26, 2025).
- When is the next earnings report from TiumBio?
- Korean companies rarely announce results dates in advance. Based on when TiumBio filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own TiumBio?
- Yes. The National Pension Service held 0.31% of TiumBio shares as of Dec 31, 2025.
Company profile
Tiumbio is a Korean biopharmaceutical company that researches and develops treatments for rare and intractable diseases, using both small-molecule synthetic drugs and biologic drugs. Its lead pipeline candidate, Tosposertib (TU2218), is a dual TGF-beta and VEGF inhibitor being developed as an anticancer immunotherapy, and the company also runs a natural cosmetics OEM/ODM business and a contract analytical development organization for biopharmaceuticals.
Written by AI from the company's latest annual report.
- Korean name
- 티움바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김훈택
- Founded
- Dec 2016
- Listed
- Nov 2019
- Listed shares
- 30,038,475
- Fiscal year ends
- Month 12
- Website
- www.tiumbio.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent news
Recent filings
See all- 5%+ holding reportOct 23, 2026
- Sale of shares in another companySep 30, 2026
- Notice on Grant of Stock Purchase OptionsSep 30, 2026
- [Amended] Notice of Stock Purchase Option GrantSep 30, 2026
- [Amended] Notice of Stock Purchase Option GrantSep 30, 2026
Titles in Korean until English translations are added.
Also known as: TiumBio / 티움바이오 / 321550 / KRX:321550
Source: KRX statistical information